Loading
A phase 1/2 trial of Rituximab, Glofitamab, Obinutuzumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Bristol-Myers Squibb, now recruiting.
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas is a phase 1/2 interventional study registered as NCT06090539 by Bristol-Myers Squibb, with 460 participants planned, started 2023-12-29 and due to reach its primary completion in 2027-10-28. Interventions recorded: BMS-986458, Rituximab, Glofitamab/Obinutuzumab, Mosunetuzumab, Epcoritamab. Conditions listed: Relapsed/Refractory Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mosunetuzumab, Epcoritamab, Glofitamab, Obinutuzumab.
Shares Golcadomide, Obinutuzumab, Rituximab, Bristol Myers Squibb.
Shares Glofitamab, Obinutuzumab, Rituximab, Hodgkin lymphoma.
Shares Mosunetuzumab, Glofitamab, Obinutuzumab, Non-Hodgkin lymphoma (all types).
Shares Mosunetuzumab, Epcoritamab, Glofitamab, Obinutuzumab.
Shares Golcadomide, Rituximab, Bristol Myers Squibb, Non-Hodgkin lymphoma (all types).
Shares Mosunetuzumab, Rituximab, Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares Glofitamab, Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/